Investigation of Serum Folate-Receptor-1 in Patients with Non- Small Cell Lung Cancer

Objective: Histopathological overexpression of folate receptor-1(FOLR1) involved in folate transport in cell growth has been reported in various cancers. Increased serum FOLR1 (sFOLR1) has also been reported in epithelial ovarian cancer. The aim was to investigate sFOLR1 levels in non-small cell lung cancer(NSCLC) patients and the response prediction of the standard chemotherapy targeting folic acid metabolism. Methods: In this prospective study, sFOLR1 levels were investigated in 30 healthy individuals and 60 patients with stage4 malign metastatic NSCLC before and after standard chemotherapy. The commercial immunoassay(ELISA) kit was used for the analysis of sFOLR1. Serum carcinoembryonic antigen(CEA), vitamin B12, and folate levels were also investigated. Results: In NSCLC patients sFOLR1 levels were significantly higher(p<0.001) than the healthy individuals. After 3 months of standard treatment, sFOLR1 was significantly lower than pre-treatment values in NSCLC patients(p<0.001). Diagnostic accuracy was strong in the differentiation of NSCLC patients from healthy individuals(AUC= 0.966). with the cut-off point of 82.45 pg/ml, the sFOLR1 level was performed with 95% sensitivity and 99% specificity. Pretreatment sFOLR1 levels were significantly lower in patients with-response to standard chemotherapy(p<0.01). The best predictive value was determined as 393.80 pg/ml. At the end of the 401 days, a significant difference was found in patients with high sFOLR1 predictive value. The median overall survival(OS) duration was 288 days for all patients (95% GA 198.13-377.87). Median progression-free survival(PFS) was 321 days(95% GA 211.90-430.10). Conclusions: For monitoring standard chemotherapy with drugs targeting folic acid metabolism, sFOLR-1 levels be an biomarker

nvestigation of Serum Folate-Receptor-1 in Patients with Non- Small Cell Lung Cancer

Objective: Histopathological overexpression of folate receptor-1(FOLR1) involved in folate transport in cell growth has been reported in various cancers. Increased serum FOLR1 (sFOLR1) has also been reported in epithelial ovarian cancer. The aim was to investigate sFOLR1 levels in non-small cell lung cancer(NSCLC) patients and the response prediction of the standard chemotherapy targeting folic acid metabolism. Methods: In this prospective study, sFOLR1 levels were investigated in 30 healthy individuals and 60 patients with stage4 malign metastatic NSCLC before and after standard chemotherapy. The commercial immunoassay(ELISA) kit was used for the analysis of sFOLR1. Serum carcinoembryonic antigen(CEA), vitamin B12, and folate levels were also investigated. Results: In NSCLC patients sFOLR1 levels were significantly higher(p<0.001) than the healthy individuals. After 3 months of standard treatment, sFOLR1 was significantly lower than pre-treatment values in NSCLC patients(p<0.001). Diagnostic accuracy was strong in the differentiation of NSCLC patients from healthy individuals(AUC= 0.966). with the cut-off point of 82.45 pg/ml, the sFOLR1 level was performed with 95% sensitivity and 99% specificity. Pretreatment sFOLR1 levels were significantly lower in patients with-response to standard chemotherapy(p<0.01). The best predictive value was determined as 393.80 pg/ml. At the end of the 401 days, a significant difference was found in patients with high sFOLR1 predictive value. The median overall survival(OS) duration was 288 days for all patients (95% GA 198.13-377.87). Median progression-free survival(PFS) was 321 days(95% GA 211.90-430.10). Conclusions: For monitoring standard chemotherapy with drugs targeting folic acid metabolism, sFOLR-1 levels may be an important biomar

Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T-cell infiltration

Aim of the study Although early diagnosis of breast cancer (BC) is often associated with a good prognosis, there is currently no biomarker with high sensitivity serving this purpose. B7H3, a recently identified member of the B7 family, appears to inhibit antitumor immunity. We investigated the soluble B7H3 (sB7H3) level in BC and its relationship with clinicopathological variables and stromal tumor-infiltrating lymphocytes (sTILs). Material and methods: The study which was designed as a cross-sectional trial between January 2020 and September 2021, included 93 BC patients, 20 patients with benign breast disease (BBD) and 14 healthy volunteers as the control group. Serum sB7H3 levels were measured using the ELISA (enzyme-linked immunosorbent assay) method and sTlLs were measured by immunohistochemistry using Tru-cut biopsy materials. Results: sB7H3 levels in BC patients were significantly higher than those in patients with BBD and healthy volunteers. Receiver operating characteristic curve analysis results showed that sB7H3 level may be a potential biomarker for distinguishing patients with BC from those with BBD (AUC: 0.807; sensitivity: 0.786; specificity: 0.706) and from healthy volunteers (AUC: 0.731; sensitivity: 0.700; spedicity: 0.692). Conclusions: To the best of our knowledge, the present study is the first to investigate the relationship between sB7H3 and disease parameters in BC. We found that sB7H3 may be a clinically practical and meaningful biomarker in differentiating BC from BBD. In order to evaluate the relationship of B7H3 with clinical variables in BC, and especially with sTILs, tissue-based studies with higher numbers of patients are needed

Videoendoscopic sentinel lymph node detection with icg and bilateral inguinofemoral lymphadenectomy in vulvar cancer comba- ozdemir technique

The authors present a surgical film for vulvar cancer surgery, which was performed via video endoscopy. An 88-year-old woman with squamous cell carcinoma of the vulva and who underwent radical vulvectomy was treated with sentinel lymph node (SLN) and bilateral inguinofemoral lymphadenectomy, which is preferably performed via video endoscopic surgery with a near-infrared fluorescence video endoscopy system. SLN mapping was performed using indocyanine green (ICG) and near-infrared fluorescence mapping. SLNs were detected in the left superficial inguinal area. The surgeons performed bilateral inguinofemoral lymphadenectomy. No postoperative early or late complications developed, and the patient was discharged 7 days after surgery. Stage 1B vulvar cancer was identified

Histerektomide robotik veya laparoskopik yaklaşım: Operatif sonuçlar ve maliyet karşılaştırılması

Purpose: The present study aimed to compare surgical outcomes and cost analysis of robotic-assisted surgery (RAS) and conventional laparoscopic surgery (CLS) hysterectomy procedures. Materials and Methods: The patients who underwent total robotic hysterectomy or total conventional laparoscopic hysterectomy with or without bilateral salpingo-oophorectomy due to benign gynecological disorders such as uterine fibroid, abnormal uterine bleeding, endometrial hyperplasia, adenomyosis, persistent ovarian cysts, chronic pelvic pain were retrospectively evaluated. Results: A total of 80 women underwent RAS or CLS hysterectomy during the study period. The mean total operative time was 187 +/- 10 min. in RAS and 133 +/- 24 min. in CLS groups, respectively. The mean total cost of the RAS hysterectomy group was 17.710 TL, and CLS hysterectomy group was 7000 TL. Conclusion: Both CLS and RAS hysterectomies for benign gynecological indications are safe surgical procedures with negligible complication rates. RAS is a more expensive procedure compared to CLS.Amaç: Bu çalışma, robotik yardımlı cerrahi (RAC) ve geleneksel laparoskopik cerrahi (GLC) histerektomi prosedürlerinin cerrahi sonuçlarını ve maliyet analizini karşılaştırmayı amaçlamaktadır. Gereç ve Yöntem: Uterin fibroid, anormal uterin kanama, endometrial hiperplazi, adenomiyozis, persiste eden over kistleri, kronik pelvik ağrı gibi benign jinekolojik bozukluklar nedeniyle bilateral salpingo-ooferektomi ile birlikte veya salpingo-ooferektomi olmaksızın total robotik histerektomi veya total konvansiyonel laparoskopik histerektomi uygulanan hastalar geriye dönük olarak değerlendirildi. Bulgular: Çalışma dönemi sırasında toplam 80 kadına RAC veya GLC histerektomi yapıldı. Ortalama toplam ameliyat süresi RAC ve GLC gruplarında sırasıyla 187 ± 10 dk. ve 133 ± 24 dk. idi . RAC histerektomi grubunun ortalama toplam maliyeti 17.710 TL ve GLC histerektomi grubunun 7000 TL idi. Sonuç: İyi huylu jinekolojik endikasyonlar için hem GLC hem de RAC histerektomiler ihmal edilebilir komplikasyon oranları ile güvenli cerrahi prosedürlerdir. Maliyetlerle ilgili olarak, RAC, GLC 'ye göre daha pahalı bir prosedürdür

Evaluation of genital self-image and sexual dysfunction in women with vulvar lichen planus or lichen sclerosus

Introduction Vulvar lichen planus (LP) and vulvar lichen sclerosus (LS) are chronic inflammatory diseases that affect women’s sexual health. In this study, our aim was to investigate sexual function, anxiety level and genital self-image in vulvar LP and vulvar LS patients. Methods This study was conducted on a total of 178 women who presented to the gynecology clinic between February 2019 and January 2020. The patients were divided into the following groups: group 1, vulvar LP (n = 21); group 2, vulvar LS (n = 59); group 3, fungal vulvitis controls (n = 48); and group 4, healthy controls (n = 50). The validated Female Sexual Function Index (FSFI), Beck Anxiety Index (BAI), and Female Genital Self-Image Scale (FGSIS) questionnaires were assessed in all women. Results There were no significant differences among the groups with respect to age, parity, menopausal status, body mass index (BMI), vaginal intercourse past 1 month, marital status or educational status (p > .05). There were statistically significant differences between the vulvar LP and vulvar LS groups compared to control groups in terms of FSFI total scores and subscores (p < .001). When FGSIS and BAI scores were analyzed, significant statistical differences were found among the study groups (p < .001). A positive correlation was found between the FSFI and FGSIS scores in patients with vulvar LP and LS. Additionally, a negative correlation was found between the FSFI and BAI scores in patients with vulvar LP and LS. Conclusions Our study showed that sexual function, genital self-image and anxiety level were associated in vulvar LP and vulvar LS patients. Vulvar LP and vulvar LS patients with worse genital self-image have more sexual problems and anxious conditions

Antibiotic consumption, resistance data, and prevention strategies

WOS: 000463053800025Dünyada ve ülkemizde antibiyotik tüketiminin artışına ilişkin veriler alarm vermektedir. Aşırı tüketim artan antibiyotik direncini tetiklemektedir. Ne yazık ki ülkemiz antibiyotik direncinin en fazla yaşandığı ülkelerdendir. Bu sorunları yenmek için son yıllarda ciddi çabalar verilse de halen alınması gereken çok yol vardır. Bugün hastanelerde antibiyotik tüketimi, tüketimin değerlendirilmesi ve strateji geliştirilmesi için antibiyotik yönetişimi kullanılmaktadır. Bu raporda, antibiyotik yönetişiminin başlıca bileşenleri, antibiyotik tüketiminin global ve ülkemiz genelindeki durumu, direnç verileri, direnci engellemeye yönelik stratejilerin değerlendirilmesi ve alınması gereken önlemlerin güncel veriler eşliğinde ortaya konulması amaçlanmıştır.Antibiotic consumption in the world and in our country. has reached alarm dimensions. This over-consumption has also made antibiotic resistance a major problem. Unfortunately, our country is one of the countries where antibiotic resistance is experienced. Serious efforts have been made in recent years to overcome these problems. However, there are still many distances to be taken. Today, evaluation of antibiotic consumption and consumption in hospitals is determined by antibiotic stewardship. In this report, antibiotics governance, antibiotic consumption in global and country-wide status, resistance data, evaluation of strategies to prevent resistance and measures to be taken are aimed